Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3301
Xenetic Biosciences
XBIO
$5.08M
| $97K | ﹤0.01% |
24,750
-2,014
| -8% | -$5.82K |
2024 Q3
3 quarters
|
|
|
RSVR
3302
Reservoir Media
RSVR
$622M
| $96.6K | ﹤0.01% |
12,600
+200
| +2% | +$1.47K |
2023 Q4
6 quarters
|
|
|
GURE
3303
Gulf Resources
GURE
$4.99M
| $96.4K | ﹤0.01% |
14,344
-474
| -3% | -$3.18K |
2013 Q2
48 quarters
|
|
|
RTB
3304
RTB Digital
RTB
$122M
| $95.3K | ﹤0.01% |
3,199
+2,085
| +187% | +$58.9K |
2024 Q2
4 quarters
|
|
3305
Yunhong Green CTI Ltd
YHGJ
$7.18M
| $94.7K | ﹤0.01% |
11,157
-210
| -2% | -$1.9K |
2016 Q3
35 quarters
|
|
3306
GT Biopharma
GTBP
$11.3M
| $94.2K | ﹤0.01% |
+1,052
| New | +$68K |
2025 Q2
0 quarters
|
|
|
FLX
3307
BingEx Ltd
FLX
$113M
| $93.2K | ﹤0.01% |
+29,600
| New | +$77.5K |
2025 Q2
0 quarters
|
|
|
RJET
3308
Republic Airways Holdings
RJET
$810M
| $93.2K | ﹤0.01% |
6,680
-6,508
| -49% | -$98.8K |
2020 Q4
18 quarters
|
|
|
YI
3309
111 Inc
YI
$27.7M
| $92.9K | ﹤0.01% |
13,014
+200
| +2% | +$1.57K |
2020 Q1
21 quarters
|
|
3310
Stereotaxis
STXS
$110M
| $92.9K | ﹤0.01% |
43,800
-78,309
| -64% | -$159K |
2022 Q1
13 quarters
|
|
3311
ABVC BioPharma
ABVC
$27M
| $92.8K | ﹤0.01% |
+41,706
| New | +$56.8K |
2025 Q2
0 quarters
|
|
3312
Immunic
IMUX
$114M
| $92.2K | ﹤0.01% |
13,215
-53,731
| -80% | -$493K |
2023 Q1
9 quarters
|
|
3313
Alpha Tau Medical
DRTS
$1.34B
| $91.7K | ﹤0.01% |
+29,400
| New | +$82.8K |
2025 Q2
0 quarters
|
|
3314
Anixa Biosciences
ANIX
$102M
| $91.3K | ﹤0.01% |
27,673
+6,200
| +29% | +$17.7K |
2024 Q3
3 quarters
|
|
|
PPSI
3315
Pioneer Power Solutions
PPSI
$34.5M
| $91.1K | ﹤0.01% |
+33,144
| New | +$89K |
2025 Q2
0 quarters
|
|
3316
Cue Biopharma
CUE
$196M
| $91.1K | ﹤0.01% |
4,449
+3,217
| +261% | +$68.6K |
2025 Q1
1 quarter
|
|
3317
Bridgford Foods
BRID
$51.6M
| $90.9K | ﹤0.01% |
11,500
| – | – |
2024 Q4
2 quarters
|
|
|
LGO
3318
Largo
LGO
$54.1M
| $90.7K | ﹤0.01% |
70,300
+34,900
| +99% | +$48.9K |
2023 Q4
6 quarters
|
|
3319
Relmada Therapeutics
RLMD
$371M
| $90.1K | ﹤0.01% |
150,100
+26,000
| +21% | +$13.3K |
2022 Q4
10 quarters
|
|
3320
SemiLEDS
LEDS
$19.1M
| $89.3K | ﹤0.01% |
34,100
+18,200
| +114% | +$44.7K |
2024 Q1
5 quarters
|
|
|
CARV
3321
DELISTED
Carver Bancorp
CARV
| $87K | ﹤0.01% |
50,300
+3,800
| +8% | +$5.54K |
2022 Q1
13 quarters
|
|
3322
Castor Maritime
CTRM
$16.9M
| $87K | ﹤0.01% |
40,669
+1,000
| +3% | +$2.23K |
2019 Q3
23 quarters
|
|
3323
DarioHealth
DRIO
$56.9M
| $87K | ﹤0.01% |
6,490
+610
| +10% | +$8.46K |
2022 Q4
10 quarters
|
|
3324
Equillium
EQ
$90M
| $86.4K | ﹤0.01% |
274,100
+4,600
| +2% | +$1.84K |
2022 Q2
12 quarters
|
|
|
STRM
3325
DELISTED
Streamline Health Solutions
STRM
| $84.9K | ﹤0.01% |
16,357
-300
| -2% | -$1.03K |
2015 Q2
40 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.